Lymphocyte actinomycin binding capacity in chronic lymphocytic leukaemia

Chronic lymphocytic leukaemia.

Chronic lymphocytic leukaemia is the commonest of the leukaemias and occurs most often in the elderly. The identification of presenting features that correlate adversely or favourably with survival has allowed the rational development of new treatment strategies.

Chronic lymphocytic leukaemia (CLL)

Typically, proliferation of mature small lymphocytes of normal morphology; lymphocytes with more abundant cytoplasm may be present. When prolymphocytes are 10% or greater they are classified as 'chronic lymphocytic leukaemia-prolymphocytic leukaemia'. The main immunophenotypic features that define BCLL are: the predominant population shares B-cell markers CD19, CD20, and CD23 with the CD5 antig...

Autoimmunity in chronic lymphocytic leukaemia.

Seventy-nine patients with chronic lymphocytic leukaemia were evaluated for the presence of autoimmune diseases and autoantibodies. One patient has polymyositis and two additional patients presented with features suggestive of pernicious anaemia and chronic active hepatitis. The Coombs' direct test was positive in 7% and immune thrombocytopenia was present in 8.1% of patients. Five (7%) patient...

Autoimmunity in chronic lymphocytic leukaemia.

The prevalence of autoantibodies in B cell chronic lymphocytic leukaemia (B-CLL) was investigated. A lower prevalence of autoimmune haemolytic anaemia than that found in other series was found: large numbers of non-progressive stage A disease cases were included, in which the prevalence of autoimmune haemolytic anaemia is low. Non-haematological autoantibodies were no commoner than in age match...

Heat Shock Proteins in Chronic Lymphocytic Leukaemia